Compare Cronos Group Inc (CRON) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs JPMorgan Chase & Co — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while JPMorgan Chase & Co trades at $332.94 (market cap $880.98B). The key difference: JPMorgan Chase & Co is far larger — about 746.6× Cronos Group Inc's market cap, and JPMorgan Chase & Co pays a 1.99% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and JPMorgan Chase & Co for 127 Days on average.
| CRON | JPM | |
|---|---|---|
Market Cap | $1.18B | $880.98B |
Volume | 968,037 | 7,721,661 |
Sector | Health | Financials |
52-Week High | $3.55 | $365.18 |
52-Week Low | $2.30 | $282.84 |
Typical Hold Time | 22 Days | 127 Days |
Enterprise Value | $387.62M | $1.82T |
Dividend Yield | — | 1.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.24, down 1.37% today amid a bearish technical signal. Recent quarterly earnings show beats in Q1 and Q2 2026, with revenue growth from $118M in 2024 to $147M in 2025. The company reported a net loss of $9.45M in 2025 but projects a profit of $70M for 2026. Analyst sentiment is mixed with a 20% buy rating. News highlights focus on international expansion and a recent Investor Day outlining growth strategies.
Outlook is cautiously optimistic given projected profitability in 2026 and strong cash reserves, but risks include sustained negative cash flow and competitive pressures. The stock's valuation metrics like P/E of 16.95 and P/S of 6.84 suggest moderate pricing relative to peers, though high EV/EBITDA of 43 indicates premium expectations.
JPMorgan Chase & Co. (JPM) trades at $332.39, up 0.85% daily, with a bearish technical signal but strong fundamentals. Recent earnings show two beats out of three reported quarters, with Q3 2026 results pending. Revenue grew to $181.85B in 2025, though net income dipped to $57.05B. The stock is supported by a high ROE of 18.43% and a moderate P/E of 14.2, while analyst consensus is a 'Moderate Buy' with a $373.18 price target.
Outlook remains positive due to solid profitability and institutional support, but risks include geopolitical tensions, cybersecurity threats highlighted in recent news, and volatile cash flows. The stock offers value relative to peers, with upside potential if earnings momentum continues, though investors should monitor macroeconomic headwinds and upcoming Q3 earnings for direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
